Contrasting Surmodics (SRDX) & The Competition

Surmodics (NASDAQ: SRDX) is one of 81 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Surmodics to related companies based on the strength of its institutional ownership, risk, analyst recommendations, dividends, valuation, profitability and earnings.

Analyst Ratings

This is a breakdown of recent recommendations for Surmodics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surmodics 0 1 2 0 2.67
Surmodics Competitors 207 1201 2683 86 2.63

Surmodics currently has a consensus target price of $40.00, indicating a potential upside of 33.33%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.60%. Given Surmodics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Surmodics is more favorable than its rivals.

Insider and Institutional Ownership

84.8% of Surmodics shares are owned by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 6.4% of Surmodics shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Surmodics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Surmodics $73.11 million $3.92 million 103.45
Surmodics Competitors $975.11 million $120.37 million 213.66

Surmodics’ rivals have higher revenue and earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Surmodics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Surmodics 5.37% 6.18% 5.11%
Surmodics Competitors -126.58% -39.95% -10.87%

Volatility & Risk

Surmodics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Surmodics’ rivals have a beta of 0.98, indicating that their average share price is 2% less volatile than the S&P 500.

Summary

Surmodics beats its rivals on 7 of the 13 factors compared.

Surmodics Company Profile

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

What are top analysts saying about Surmodics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Surmodics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit